Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases.
We reviewed Food and Drug Administration postmarketing reports of central nervous system (CNS) anticholinergic effects in association with oxybutynin. Taking domestic usage by age group into account, there is a disproportionately higher number of CNS adverse event cases reported in pediatric patients as compared with adult patients. CNS stimulation was prominent in the pediatric cases.
Gish
Paula
P
Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, The United States Food and Drug Administration, Silver Spring, MD 20993, USA. paula.gish@fda.hhs.gov
Mosholder
Andrew D
AD
Truffa
Melissa
M
Johann-Liang
Rosemary
R
D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D000367:Age Factors; D002490:Central Nervous System / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D019992:Databases as Topic; D006801:Humans; D007223:Infant; D008333:Mandelic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D009422:Nervous System Diseases / Q000139:chemically induced*; D053206:Nocturnal Enuresis / Q000188:drug therapy; D055815:Young Adult
D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin